Copayment accumulators and maximizers have the potential to harm patients’ access to necessary medicines. Health care payers (including employers, insurers, and pharmacy benefit managers), regulators, ...

If left unchecked, the power of PBMs and their complex relationships within the American healthcare system could lead to higher drug costs and diminished returns.

Policymakers at the federal and state level have considered a number of reforms, many of which have bipartisan support, to ...

If you ask any Missouri family what's stretching their wallets the most, you'll likely hear the same thing: higher prices on everything.

Virginia can and should tackle prescription drug affordability, but not with policies that create more problems than they ...

Choosing the right Medicare plan is essential for ensuring you have the coverage that best meets your health care and financial needs. However, as your health, budget and provider networks change, ...

Gov. Kathy Hochul announced Monday a new program, “DFS Connect,” that will make it easier for New Yorkers to file complaints ...

Generic drugmakers and hospital pharmacists warn that added financial pressure from tariffs could strain the nation's generic ...

Warning that the state’s health care system is “falling apart,” the Senate’s point person on the topic said that she wants to ...

The Office of Insurance Regulation is demanding the unusual trove of data from pharmacy benefit managers — health care ...

Yet another suit alleges an ERISA fiduciary breach regarding the administration of a corporate healthcare plan.

Dwindling supplies of Ozempic are fuelling an “exploding” black market for the drug across Australia, as the medical industry is forced to assess which patients need the popular medication the most.